Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Genetics(clinical),General Medicine
Reference51 articles.
1. European Parliament C of the EU. Regulation (EC) No 141/2000 of the European Parliament and of the Council of 16 December 1999 on orphan medicinal products. Official Journal of the European Communities.
https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf
. Published 2000. Accessed 12 Oct 2018..
2. Jonker A, Mills A, Lau L, et al., eds. Small Population Clinical Trials: Challenges in the Field of Rare Diseases. 2016.
http://www.irdirc.org/wp-content/uploads/2017/12/SPCT_Report.pdf
. Accessed 12 Oct 2018.
3. Roberts SA, Allen JD, Sigal EV. Despite criticism of the FDA review process, new Cancer drugs reach patients sooner in the United States than in Europe. Health Aff. 2011;30(7):1375–81.
https://doi.org/10.1377/hlthaff.2011.0231
.
4. Kesselheim AS, Myers JA, Avorn J. Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA. 2011;305(22):2320–6.
https://doi.org/10.1001/jama.2011.769
.
5. Jonsson B, Bergh J. Hurdles in anticancer drug development from a regulatory perspective. Nat Rev Clin Oncol. 2012;9(4):236–43.
https://doi.org/10.1038/nrclinonc.2012.14
.
Cited by
40 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献